Skip to main content

Table 3 Absolute decline in FVC percentage of predicted value (compared with baseline) over 12 months

From: Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials

  Placebo group Cyclophosphamide group
  Number of subjects Absolute decline in FVC % predicted, mean (SD) p Value Number of subjects Absolute decline in FVC % predicted, mean (SD) p Value
Visual maximum fibrosis score
 0–25 % 19 0.1 (9.0) 0.019 13 −3.4 (6.3) 0.04
 26–100 % 29 −6.2 (8.3) 30 1.2 (6.6)
Goh and Wells criteria, unadjusted stratification
 <20 % 22 −1.6 (10.2) 0.15 15 −1.0 (6.7) 0.49
 >20 % 25 −5.5 (8.0) 30 0.6 (7.7)  
Goh and Wells criteria with indeterminate results on HRCT (10–30 %), adjusted stratification
 Minimal disease 8 2.2 (9.8) 0.08 12 −1.1 (4.3) 0.47
 Extensive disease 39 −4.9 (8.7) 32 0.3 (8.2)
QILD WL
 <20 % 10 0.3 (6.8) 0.07 5 −7.9 (9.7) 0.12
 >20 % 37 −4.9 (9.5)   38 0.8 (5.7)  
QILD ZM
 <25 % 2 5.0 (7.5) 0.32 2 −12.3 (1.5) 0.001
 >25 % 45 −4.1 (9.1) 41 0.4 (6.4)
QLF WL
 <20 % 42 −3.0 (9.1) 0.16 39 −0.4 (6.7) 0.70
 >20 % 5 −9.8 (8.7) 4 1.4 (8.2)
QLF ZM
 <25 % 27 −1.4 (10.1) 0.03 24 −1.2 (7.2) 0.26
 >25 % 20 −6.9 (6.8) 19 1.1 (6.2)
  1. FVC % predicted percentage of predicted forced vital capacity, HRCT high-resolution computed tomography, QILD WL quantitative assessment of total extent of interstitial lung disease in whole lung, QILD ZM quantitative assessment of total extent of interstitial lung disease in zone of maximal involvement, QLF WL quantitative percentage with fibrosis in whole lung, QLF ZM quantitative percentage with fibrosis in zone of maximal involvement, SD standard deviation Negative score denotes worsening in FVC